ZA987810B - A combination of a selective 5HT1A antagonist and a selective h5-HT1B antagonist or partial agonist - Google Patents

A combination of a selective 5HT1A antagonist and a selective h5-HT1B antagonist or partial agonist

Info

Publication number
ZA987810B
ZA987810B ZA987810A ZA987810A ZA987810B ZA 987810 B ZA987810 B ZA 987810B ZA 987810 A ZA987810 A ZA 987810A ZA 987810 A ZA987810 A ZA 987810A ZA 987810 B ZA987810 B ZA 987810B
Authority
ZA
South Africa
Prior art keywords
selective
antagonist
combination
partial agonist
ht1b
Prior art date
Application number
ZA987810A
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA987810B publication Critical patent/ZA987810B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA987810A 1997-09-18 1998-08-27 A combination of a selective 5HT1A antagonist and a selective h5-HT1B antagonist or partial agonist ZA987810B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703374A SE9703374D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (1)

Publication Number Publication Date
ZA987810B true ZA987810B (en) 1999-02-18

Family

ID=20408294

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA987810A ZA987810B (en) 1997-09-18 1998-08-27 A combination of a selective 5HT1A antagonist and a selective h5-HT1B antagonist or partial agonist

Country Status (30)

Country Link
US (1) US6159972A (sv)
EP (1) EP1021183B1 (sv)
JP (1) JP2001516717A (sv)
KR (1) KR20010024075A (sv)
CN (1) CN1182847C (sv)
AR (1) AR015447A1 (sv)
AT (1) ATE261728T1 (sv)
AU (1) AU752718B2 (sv)
BR (1) BR9812234A (sv)
CA (1) CA2302383A1 (sv)
DE (1) DE69822490T2 (sv)
DK (1) DK1021183T3 (sv)
EE (1) EE04142B1 (sv)
ES (1) ES2216307T3 (sv)
HK (1) HK1032740A1 (sv)
HU (1) HUP0100401A3 (sv)
IL (1) IL134774A0 (sv)
IS (1) IS5408A (sv)
MY (1) MY116281A (sv)
NO (1) NO20001398L (sv)
NZ (1) NZ503174A (sv)
PL (1) PL339370A1 (sv)
PT (1) PT1021183E (sv)
RU (1) RU2215528C2 (sv)
SE (1) SE9703374D0 (sv)
SK (1) SK2842000A3 (sv)
TR (1) TR200000734T2 (sv)
TW (1) TW568786B (sv)
WO (1) WO1999013876A1 (sv)
ZA (1) ZA987810B (sv)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
WO2003007956A1 (en) * 2001-07-20 2003-01-30 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
USD969017S1 (en) 2021-06-28 2022-11-08 Koninklijke Asscher Diamant Maatschappij B.V. Rose marquise diamond article

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
FI961247A0 (fi) * 1996-03-18 1996-03-18 Finnish Peroxides Ab Oy Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
TR200000734T2 (tr) 2000-11-21
SE9703374D0 (sv) 1997-09-18
MY116281A (en) 2003-12-31
DE69822490D1 (de) 2004-04-22
HK1032740A1 (en) 2001-08-03
AR015447A1 (es) 2001-05-02
BR9812234A (pt) 2000-07-18
ES2216307T3 (es) 2004-10-16
HUP0100401A3 (en) 2003-01-28
EP1021183A1 (en) 2000-07-26
NO20001398D0 (no) 2000-03-17
PT1021183E (pt) 2004-07-30
CN1182847C (zh) 2005-01-05
AU752718B2 (en) 2002-09-26
EE04142B1 (et) 2003-10-15
TW568786B (en) 2004-01-01
WO1999013876A1 (en) 1999-03-25
IL134774A0 (en) 2001-04-30
JP2001516717A (ja) 2001-10-02
EE200000143A (et) 2001-02-15
ATE261728T1 (de) 2004-04-15
EP1021183B1 (en) 2004-03-17
PL339370A1 (en) 2000-12-18
IS5408A (is) 2000-03-15
NO20001398L (no) 2000-04-04
NZ503174A (en) 2002-03-01
DE69822490T2 (de) 2005-03-03
RU2215528C2 (ru) 2003-11-10
CN1279609A (zh) 2001-01-10
HUP0100401A2 (hu) 2002-01-28
US6159972A (en) 2000-12-12
AU9192998A (en) 1999-04-05
SK2842000A3 (en) 2000-09-12
KR20010024075A (ko) 2001-03-26
DK1021183T3 (da) 2004-07-05
CA2302383A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
PL337781A1 (en) Antagonists and reverse antagonists of glucogene
HK1124339A1 (en) 20-keto-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal activity 20--11-
EP1047426A4 (en) USE OF METHYLNALTREXONE AND RELATED COMPOUNDS
EP1009415A4 (en) INHIBITORS OF $ g (b) -LACTAMASES AND THEIR USES
EP1037635A4 (en) CONNECTIONS AROUND METHODS
HUP0101948A3 (en) Il-2 selective agonists and antagonists
IL130660A0 (en) Benzothiophenecarboxamide derivatives and PGD2 antagonists comprising them
PL334846A1 (en) Sulphamidic inhibitors of metaloproteases
ZA987817B (en) A combination of a 5-HT reuptake inhibitor and a h5-HT1b antagonist or partial agonist
IL117988A0 (en) A new combination of an inhibitor and an antagonist
PL341114A1 (en) Antagonists of thrombosin receptors
ZA988749B (en) New pieperazine and piperidine compounds
ZA987804B (en) A combination of a monoamine oxidase inhibitor and a H5-HT1b antagonists or agonist
GB2338014B (en) Novel drilling device and method of use
ZA98256B (en) Tachykinin antagonists
GB9704349D0 (en) Levobupivacaine and its use
ZA987810B (en) A combination of a selective 5HT1A antagonist and a selective h5-HT1B antagonist or partial agonist
GB9820014D0 (en) Receptor antagonists and uses thereof
ZA987793B (en) Roof-bolt drilling and setting apparatus
GB9704370D0 (en) Levobupivacaine and its use
SI1021183T1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
PL102492U1 (en) Boring and facing head
GB9722023D0 (en) Levobupivacaine and its use
GB9716815D0 (en) Hole cutting and forming apparatus
GB2321203B (en) Gaming-table and barrier therefor